EDSA
Edesa Biotech Inc

12,728
Loading...
Loading...
News
all
press releases
Edesa Biotech Showcases Steady Q3 2024 Financials
Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, has announced its third-quarter financials...
TipRanks Financial Blog·1y ago
News Placeholder
More News
News Placeholder
Edesa Biotech to Participate in Upcoming Investor Conferences
TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
Accesswire·1y ago
News Placeholder
Pardeep Nijhawan Acquires 5,000 Shares of Edesa Biotech, Inc. (NASDAQ:EDSA) Stock
Edesa Biotech, Inc. (NASDAQ:EDSA Get Free Report) CEO Pardeep Nijhawan purchased 5,000 shares of the companys stock in a transaction dated Monday, March 25th. The shares were bought at...
Ticker Report·1y ago
News Placeholder
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
Accesswire·1y ago
News Placeholder
Edesa Biotech to Participate in Barclays Global Healthcare Conference
TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
Accesswire·2y ago
News Placeholder
Edesa Biotech to Participate in Upcoming Dermatology Meetings
TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
Accesswire·2y ago
News Placeholder
Edesa Biotech, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.61) Per Share (NASDAQ:EDSA)
Edesa Biotech, Inc. (NASDAQ:EDSA Free Report) Research analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Edesa Biotech in a research note issued to investors...
Zolmax·2y ago
News Placeholder
Edesa Biotech (NASDAQ:EDSA) Earns "Buy" Rating from HC Wainwright
Edesa Biotech (NASDAQ:EDSA Get Free Report)s stock had its buy rating restated by research analysts at HC Wainwright in a research report issued to clients and investors...
Zolmax·2y ago
News Placeholder
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
Accesswire·2y ago
News Placeholder
Brookline Capital Management Comments on Edesa Biotech, Inc.'s Q1 2024 Earnings (NASDAQ:EDSA)
Edesa Biotech, Inc. (NASDAQ:EDSA Free Report) Equities researchers at Brookline Capital Management issued their Q1 2024 earnings per share estimates for shares of Edesa Biotech in a...
Zolmax·2y ago

Latest EDSA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.